Stock SAGENT PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Sagent Pharmaceuticals Inc

Equities

US7866921031

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Sagent Pharmaceuticals Inc
2016 Allergan : Teva, Allergan win U.S. antitrust approval for generics deal RE

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nichi-Iko Pharmaceutical Co., Ltd. : Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.
BU
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10 g due to presence of iron oxide particulate matter
GL
Nichi-Iko Pharmaceutical Co., Ltd. : Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.
BU
Sagent Pharmaceuticals : Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash Tender Offer of $21.75 Net Per Share to Acquire All Outstanding Shares of Sagent Pharmaceuticals, Inc.
BU
Allergan : Teva, Allergan win U.S. antitrust approval for generics deal
RE
Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
BU
Sagent Pharmaceuticals : Acquisition May Not Be in the Best Interests of SGNT Shareholders
PR
Ryan & Maniskas, LLP : Announces Investigation of Sagent Pharmaceuticals, Inc.
PR
Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
BU
Nichi-Iko Pharmaceutical Co., Ltd : to Acquire Sagent Pharmaceuticals for $21.75 Per Share in All Cash Transaction
BU
Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.
GL
Sagent Pharmaceuticals : Sets Date and Time for Release of First Quarter 2016 Financial Results
PU
Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results
GL
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2016 Financial Results
GL
Sagent Pharmaceuticals Names Sean Brynjelsen Executive Vice President, Business Development
GL
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Fluconazole Injection, USP, (in 0.9% Sodium Chloride) 200mg Per 100mL Due to the Discovery of an Out of Specification Impurity Result Detected During Routine Quality Testing of Stability Samples at the 18-Month Interval
GL
Sagent Pharmaceuticals Names Frank Harmon Executive Vice President Global Operations
GL
Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results
GL
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2015 Financial Results
GL
Sagent Pharmaceuticals Receives Innovative Technology Designation From Novation for GLYDO® (Lidocaine HCl Jelly USP, 2%)
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Sagent Pharmaceuticals Inc